Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin

Journal of Clinical Pharmacology

Volumn 42, Issue 8, 2002, Pages 835-845

  Igel, Michael ^a   Sudhop, Thomas ^a   Von Bergmann, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CORTICOSTEROID; FLUINDOSTATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROLIDE; MEVINOLIN; NEUROLEPTIC AGENT; OMEPRAZOLE; OPIATE DERIVATIVE; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; ANTILIPEMIC AGENT; ENZYME INHIBITOR; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE;

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CORONARY RISK; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; REVIEW; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; METABOLISM;

ACYL COENZYME A; ANTILIPEMIC AGENTS; CORONARY DISEASE; ENZYME INHIBITORS; FLUOROBENZENES; QUINOLINES; SUPPORT, NON-U.S. GOV'T; PYRIMIDINES; SULFONAMIDES;

EID: 0035997137     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401102731     Document Type: Review

References (117)

1. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
8. Rhabdomyolysis and HMG-CoA reductase inhibitors
9. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture
10. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium
11. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase
12. Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia
13. Simvastatin: A review of its pharmacclogical properties and therapeutic potential in hypercholesterolaemia
14. Pravastatim a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
15. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
16. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
17. Preclinical review of cerivastatin sodium: A step forward in HMG-CoA reductase inhibition
18. Baycol withdrawn from market
19. A new statin: A new standard
20. NK-104: A novel synthetic HMG-CoA reductase inhibitor
21. Therapies on the horizon for cholesterol reduction
22. Novel approaches to lipid lowering: What is on the horizon?
23. A receptor-mediated pathway for cholesterol homeostasis
24. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
25. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
26. Comparison of statins in hypertriglyceridemia
27. Effects of atorvastatin in patients with homozygous familial hypercholesterolemia
28. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
29. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study
30. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
31. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension
32. Coronary plaque disruption
33. Importance of endothelial function in mediating the benefits of lipid-lowering therapy
34. Statins do more than just lower cholesterol
35. Kuopio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries
36. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
37. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b- dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
38. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth
39. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
40. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
41. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins
42. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins
43. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
44. Rho GTPases and signaling networks
45. Rho GTPases and the actin cytoskeleton
46. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down- regulation of p27(Kip1)
47. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation
48. Acute-phase proteins and other systemic responses to inflammation
49. Inflammation markers and coronary heart disease
50. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
51. C-reactive protein, inflammation, and coronary risk
52. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
53. Long-term effects of pravastatin on plasma concentration of C-reactive protein
54. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
55. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
56. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
57. Homocysteine and coronary risk
58. Homocysteine, B vitamins, and coronary artery disease
59. Association of plasma homocysteine with the number of major coronary arteries severely narrowed
60. High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia
61. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels
62. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
63. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)
64. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
65. Cytochrome P-450 3A4: Regulation and role in drug metabolism
66. "It's the genes, stupid": Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism
67. Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics
68. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin
69. Recent advances: The cytochrome P450 enzymes
70. Biotransformation of pravastatin sodium in humans
71. Biotransformation of pravastatin sodium (I): Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium
72. Clinical pharmacokinetics of pravastatin
73. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
74. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
75. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
76. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
77. ZD4522 - An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems
78. Update: Clinically significant cytochrome P-450 drug interactions
79. Gemfibrozil-induced myopathy
80. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
81. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
82. Rhabdomyolysis after taking atorvastatin with gemfibrozil
83. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
84. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
85. Statin-fibrate combination therapy
86. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
87. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
88. Lovastatin, nicotinic acid, and rhabdomyolysis
89. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
90. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth
91. Current perspectives on statins
92. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
93. The West of Scotland Coronary Prevention Study: A trial of cholesterol reduction in Scottish men
94. Learning from the cerivastatin experience
95. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial
96. Longterm efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia
97. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
98. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
99. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor
100. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
101. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
102. Disposition of a new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects
103. Pharmacodynamic effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after am and pm administration in healthy subjects
104. Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis
105. Pharmacodynamics of a new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
106. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid
107. First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104
108. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
109. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human
110. Effects of NK-104, a new hydroxymethylglutarylcoenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
111. Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia: Randomized double-blind, crossover placebo controlled study
112. Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia
113. Efficacy and safety of NK-104 (itavastatin) in hyperlipidemic patients: A double blind comparative study
114. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
115. Pharmacological properties of ZD4522: A new HMG-CoA reductase inhibitor
116. Single- and multiple dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522